N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (
DPPE,
tesmilifene), a potent chemopotentiating
drug currently in Phase III clinical trials of metastatic
breast cancer, increases cytotoxicity of
anthracyclines and
taxanes in a variety of multi-drug resistance expressing (MDR+) tumor cell lines in vitro; inhibits binding of
histamine to
CYP3A4, a
lipid/
prostanoid-regulatory P450; and modulates serum levels of HDL/
LDL cholesterol and
phospholipids in vivo. Since increased exposure of
phosphatidylserine (PS) on the outer cell membrane leaflet is associated with apoptosis, increased clearance of dead cells by phagocytes and inhibition of the
P-glycoprotein pump, the effect of
DPPE on PS synthesis was assessed in vitro in a human
breast cancer cell line. MCF-7 cells were incubated with 5 microM
DPPE for 24 hr or 5 days, followed by addition of [1-(14)C]
arachidonic acid for 4 hr; or [3H]
serine for 8 hr. Compared to untreated cells, a 27-42% (p < 0.05) increase in [1-(14)C]
arachidonic acid incorporated into all
phospholipids, including a 1.9-fold increase (p < 0.05) in PS was observed in
DPPE-treated cells. [3H]
Serine incorporation into PS was elevated 37%, while the pool size of PS was elevated 23% (p < 0.05) in
DPPE-treated cells, indicating elevated de novo PS biosynthesis. Annexin-5 binding studies indicated an elevation in exposure of PS on the surface of the plasma membrane in
DPPE-treated cells.
DPPE-treatment also resulted in N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine accumulation indicative of phospholipidosis-inducing potential. Thus, the chemopotentiating effect of
DPPE may be due to its phospholipidosis-inducing potential and stimulation of PS synthesis leading to an increased exposure of PS on the cell surface which could potentially enhance
cancer cell clearance by phagocytes.